Bp PLC Incyte Corp Transaction History

Bp PLC

  • $14.7 Million
  • Q1 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 10, 2021
SELL
$68.67 - $84.02 $319,109 - $390,440
-4,647 Closed
0 $0
Q2 2021

Aug 09, 2021
SELL
$79.87 - $87.53 $162,455 - $178,036
-2,034 Reduced 30.44%
4,647 $391,000
Q1 2021

May 13, 2021
SELL
$76.02 - $100.5 $139,496 - $184,417
-1,835 Reduced 21.55%
6,681 $543,000
Q4 2020

Feb 08, 2021
SELL
$80.74 - $97.7 $676,924 - $819,116
-8,384 Reduced 49.61%
8,516 $740,000
Q3 2020

Oct 30, 2020
SELL
$85.07 - $109.69 $119,097 - $153,566
-1,400 Reduced 7.65%
16,900 $1.52 Million
Q2 2020

Aug 05, 2020
BUY
$74.18 - $108.93 $1.36 Million - $1.99 Million
18,300 New
18,300 $1.9 Million
Q1 2020

May 05, 2020
SELL
$63.18 - $85.97 $1.19 Million - $1.62 Million
-18,800 Closed
0 $0
Q3 2019

Nov 13, 2019
BUY
$72.82 - $86.52 $58,255 - $69,216
800 Added 4.44%
18,800 $1.4 Million
Q2 2019

Jul 29, 2019
SELL
$73.52 - $88.7 $147,040 - $177,400
-2,000 Reduced 10.0%
18,000 $1.53 Million
Q4 2018

Feb 06, 2019
SELL
$58.5 - $69.94 $175,500 - $209,820
-3,000 Reduced 13.04%
20,000 $1.27 Million
Q2 2018

Jul 30, 2018
BUY
$60.85 - $83.98 $1.4 Million - $1.93 Million
23,000 New
23,000 $1.54 Million
Q4 2017

Feb 06, 2018
SELL
$93.56 - $116.6 $1.96 Million - $2.45 Million
-21,000 Closed
0 $0
Q3 2017

Oct 30, 2017
BUY
$109.15 - $138.27 $2.29 Million - $2.9 Million
21,000
21,000 $2.45 Million

Others Institutions Holding INCY

# of Institutions
619
Shares Held
215M
Call Options Held
366K
Put Options Held
445K
View Full List

About INCYTE CORP

INCY Quotes by TradingView
  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $14.7B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Bp PLC Portfolio

Follow Bp PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bp PLC, based on Form 13F filings with the SEC.

News

Stay updated on Bp PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email